W Michael Korn

Summary

Affiliation: University of California
Country: USA

Publications

  1. pmc A dynamical systems model for combinatorial cancer therapy enhances oncolytic adenovirus efficacy by MEK-inhibition
    Neda Bagheri
    Department of Biological Engineering, Massachusetts Institute of Technology, Cambridge, Massachusetts, United States of America
    PLoS Comput Biol 7:e1001085. 2011
  2. pmc Subtype-specific MEK-PI3 kinase feedback as a therapeutic target in pancreatic adenocarcinoma
    Olga K Mirzoeva
    Corresponding Author W Michael Korn, UCSF Divisions of Gastroenterology and Hematology Oncology, Helen Diller Family Comprehensive Cancer Center, 2340 Sutter St, Box 1387, San Francisco, CA 94115
    Mol Cancer Ther 12:2213-25. 2013
  3. pmc ZEB1 limits adenoviral infectability by transcriptionally repressing the coxsackie virus and adenovirus receptor
    Markus D Lacher
    Department of Medicine, Division of Gastroenterology, University of California, San Francisco, CA, USA
    Mol Cancer 10:91. 2011
  4. doi request reprint A Multicenter, Open-Label Phase II Clinical Trial of Combined MEK plus EGFR Inhibition for Chemotherapy-Refractory Advanced Pancreatic Adenocarcinoma
    Andrew H Ko
    Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, California
    Clin Cancer Res 22:61-8. 2016
  5. doi request reprint A phase 1b study of the Akt-inhibitor MK-2206 in combination with weekly paclitaxel and trastuzumab in patients with advanced HER2-amplified solid tumor malignancies
    Amy Jo Chien
    Department of Medicine, Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, 1600 Divisadero St, Box 1710, San Francisco, CA, 94115, USA
    Breast Cancer Res Treat 155:521-30. 2016
  6. doi request reprint A phase II study of bevacizumab plus erlotinib for gemcitabine-refractory metastatic pancreatic cancer
    Andrew H Ko
    University of California at San Francisco Helen Diller Family Comprehensive Cancer Center, 1600 Divisadero Street, 4th Floor, Box 1705, San Francisco, CA 94115, USA
    Cancer Chemother Pharmacol 66:1051-7. 2010
  7. ncbi request reprint Prevention and management of early esophageal cancer
    W Michael Korn
    University of California, 2340 Sutter Street, San Francisco, CA 94115, USA
    Curr Treat Options Oncol 5:405-16. 2004
  8. ncbi request reprint Inhibition of the Raf/MEK/ERK pathway up-regulates expression of the coxsackievirus and adenovirus receptor in cancer cells
    Mario Anders
    Cancer Research Institute, University of California, San Francisco 94143, USA
    Cancer Res 63:2088-95. 2003
  9. pmc Basal subtype and MAPK/ERK kinase (MEK)-phosphoinositide 3-kinase feedback signaling determine susceptibility of breast cancer cells to MEK inhibition
    Olga K Mirzoeva
    Department of Medicine, Division of Gastroenterology, University of California, San Francisco, California 94115, USA
    Cancer Res 69:565-72. 2009

Collaborators

  • Eric A Collisson
  • Alan P Venook
  • Michelle E Melisko
  • Tanios Bekaii-Saab
  • Hope S Rugo
  • Emmett Schmidt
  • Joe W Gray
  • Emily K Bergsland
  • Byron Hann
  • Andrew H Ko
  • Olga K Mirzoeva
  • Amy Jo Chien
  • Margaret A Tempero
  • R Kate Kelley
  • Elizabeth Dito
  • Neda Bagheri
  • Marisa Shiina
  • Markus D Lacher
  • Frank McCormick
  • Peter Kuhn
  • Olga M Mirzoeva
  • Craig Fancourt
  • Christina Yau
  • Nancy M Joseph
  • Mark M Moasser
  • Mario Anders
  • R Katie Kelley
  • Pamela N Munster
  • Sharvina Ziyeh
  • Ryan Courtin
  • Anna Ong
  • Laura van't Veer
  • Sanaa Tahiri
  • Jessica Van Ziffle
  • Laura J Esserman
  • Regina Linetskaya
  • Amirali Talasaz
  • Denise M Wolf
  • Alyson Cockerill
  • Yun K Hom
  • Peter M Schaefer
  • Douglas A Lauffenburger
  • Maarit I Tiirikainen
  • Peter Chang
  • Debora Keller
  • Janet Scott
  • Jimmy Hwang
  • Brian Schillinger
  • Doris Siwak
  • Mina J Bissell
  • Andrew J Wyrobek
  • Nicholas J Wang
  • Heidi S Feiler
  • Philippe Gascard
  • Zachary Knight
  • Wen Lin Kuo
  • Rina Gendelman
  • Zhi Hu
  • Yinghui Guan
  • Laura M Heiser
  • Paul T Spellman
  • Richard M Neve
  • Nora Bayani
  • Debopriya Das
  • Gordon B Mills
  • Kevan M Shokat
  • Bahram Parvin
  • Sanchita Bhattacharya
  • Christine Christian
  • Martin McMahon

Detail Information

Publications9

  1. pmc A dynamical systems model for combinatorial cancer therapy enhances oncolytic adenovirus efficacy by MEK-inhibition
    Neda Bagheri
    Department of Biological Engineering, Massachusetts Institute of Technology, Cambridge, Massachusetts, United States of America
    PLoS Comput Biol 7:e1001085. 2011
    ..Enhanced oncolytic therapy has the potential to dramatically improve non-surgical cancer treatment, especially in locally advanced or metastatic cases where treatment options remain limited...
  2. pmc Subtype-specific MEK-PI3 kinase feedback as a therapeutic target in pancreatic adenocarcinoma
    Olga K Mirzoeva
    Corresponding Author W Michael Korn, UCSF Divisions of Gastroenterology and Hematology Oncology, Helen Diller Family Comprehensive Cancer Center, 2340 Sutter St, Box 1387, San Francisco, CA 94115
    Mol Cancer Ther 12:2213-25. 2013
    ..Thus, our findings suggest a new, subtype-specific, and personalized therapeutic strategy for pancreatic cancer...
  3. pmc ZEB1 limits adenoviral infectability by transcriptionally repressing the coxsackie virus and adenovirus receptor
    Markus D Lacher
    Department of Medicine, Division of Gastroenterology, University of California, San Francisco, CA, USA
    Mol Cancer 10:91. 2011
    ..While EMT is crucial in embryonic development, it has been proposed to contribute to the formation of invasive and metastatic carcinomas by reducing cell-cell contacts and increasing cell migration...
  4. doi request reprint A Multicenter, Open-Label Phase II Clinical Trial of Combined MEK plus EGFR Inhibition for Chemotherapy-Refractory Advanced Pancreatic Adenocarcinoma
    Andrew H Ko
    Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, California
    Clin Cancer Res 22:61-8. 2016
    ....
  5. doi request reprint A phase 1b study of the Akt-inhibitor MK-2206 in combination with weekly paclitaxel and trastuzumab in patients with advanced HER2-amplified solid tumor malignancies
    Amy Jo Chien
    Department of Medicine, Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, 1600 Divisadero St, Box 1710, San Francisco, CA, 94115, USA
    Breast Cancer Res Treat 155:521-30. 2016
    ..Preclinical studies demonstrate synergy between MK-2206, a selective allosteric Akt-inhibitor, with paclitaxel and trastuzumab. We aimed to evaluate the safety of this combination in patients with HER2+ malignancies...
  6. doi request reprint A phase II study of bevacizumab plus erlotinib for gemcitabine-refractory metastatic pancreatic cancer
    Andrew H Ko
    University of California at San Francisco Helen Diller Family Comprehensive Cancer Center, 1600 Divisadero Street, 4th Floor, Box 1705, San Francisco, CA 94115, USA
    Cancer Chemother Pharmacol 66:1051-7. 2010
    ..Based on potential for additive or synergistic activity by concurrent inhibition of VEGF and EGFR, we conducted a phase II study evaluating the combination of bevacizumab plus erlotinib in this patient population...
  7. ncbi request reprint Prevention and management of early esophageal cancer
    W Michael Korn
    University of California, 2340 Sutter Street, San Francisco, CA 94115, USA
    Curr Treat Options Oncol 5:405-16. 2004
    ..For patients with adenocarcinoma of the gastroesophageal junction with submucosal involvement, adjuvant chemoradiation should be considered because of its potential to increase survival...
  8. ncbi request reprint Inhibition of the Raf/MEK/ERK pathway up-regulates expression of the coxsackievirus and adenovirus receptor in cancer cells
    Mario Anders
    Cancer Research Institute, University of California, San Francisco 94143, USA
    Cancer Res 63:2088-95. 2003
    ....
  9. pmc Basal subtype and MAPK/ERK kinase (MEK)-phosphoinositide 3-kinase feedback signaling determine susceptibility of breast cancer cells to MEK inhibition
    Olga K Mirzoeva
    Department of Medicine, Division of Gastroenterology, University of California, San Francisco, California 94115, USA
    Cancer Res 69:565-72. 2009
    ....